clinical laboratories across Europe. The IVDR approvals come in advance of the European regulatory deadline of December 2027 for HLA-typing devices. About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company...
our next-generation innovative pipeline. Anchored by our strategic goals of achieving RMB 20 billion in product revenue by 2027 and advancing five pipeline programs into global Phase 3 trials by 2030, Innovent will continue striving to become a...
portfolio and part of our broader strategy to commercialize six biosimilars across eight product presentations by 2027.” “The positive results from the confirmatory patient study represent an important step in the development of the XOLAIR®...
trial is an important step towards launching the world’s first fridge-free Tetanus & Diphtheria vaccine (SPVX02) by 2027. We have shown that our StablevaX™ technology can be manufactured under commercially scalable GMP conditions, enabling us to...
